XTRA:EUZ

Stock Analysis Report

Eckert & Ziegler Strahlen- und Medizintechnik

Executive Summary

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide.

Snowflake

Fundamentals

Flawless balance sheet with solid track record.

Share Price & News

How has Eckert & Ziegler Strahlen- und Medizintechnik's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EUZ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.9%

EUZ

2.7%

DE Medical Equipment

-0.3%

DE Market


1 Year Return

229.9%

EUZ

29.4%

DE Medical Equipment

10.4%

DE Market

Return vs Industry: EUZ exceeded the German Medical Equipment industry which returned 29.4% over the past year.

Return vs Market: EUZ exceeded the German Market which returned 10.4% over the past year.


Shareholder returns

EUZIndustryMarket
7 Day10.9%2.7%-0.3%
30 Day14.7%12.5%4.2%
90 Day16.6%13.3%12.4%
1 Year234.0%229.9%31.5%29.4%13.9%10.4%
3 Year723.9%680.0%128.5%122.5%24.9%13.9%
5 Year816.6%721.8%274.9%256.0%35.6%17.1%

Price Volatility Vs. Market

How volatile is Eckert & Ziegler Strahlen- und Medizintechnik's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eckert & Ziegler Strahlen- und Medizintechnik undervalued compared to its fair value and its price relative to the market?

42.24x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: EUZ (€180.8) is trading above our estimate of fair value (€122.74)

Significantly Below Fair Value: EUZ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: EUZ is poor value based on its PE Ratio (42.2x) compared to the Medical Equipment industry average (42.2x).

PE vs Market: EUZ is poor value based on its PE Ratio (42.2x) compared to the German market (19.7x).


Price to Earnings Growth Ratio

PEG Ratio: EUZ is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: EUZ is overvalued based on its PB Ratio (6.8x) compared to the DE Medical Equipment industry average (6x).


Next Steps

Future Growth

How is Eckert & Ziegler Strahlen- und Medizintechnik forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

24.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EUZ's forecast earnings growth (24.6% per year) is above the savings rate (0.2%).

Earnings vs Market: EUZ's earnings (24.6% per year) are forecast to grow faster than the German market (12.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: EUZ's revenue (9.3% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: EUZ's revenue (9.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EUZ's Return on Equity is forecast to be low in 3 years time (18.8%).


Next Steps

Past Performance

How has Eckert & Ziegler Strahlen- und Medizintechnik performed over the past 5 years?

17.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EUZ has high quality earnings.

Growing Profit Margin: EUZ's current net profit margins (12.3%) are higher than last year (9.6%).


Past Earnings Growth Analysis

Earnings Trend: EUZ's earnings have grown by 17.9% per year over the past 5 years.

Accelerating Growth: EUZ's earnings growth over the past year (41.1%) exceeds its 5-year average (17.9% per year).

Earnings vs Industry: EUZ earnings growth over the past year (41.1%) exceeded the Medical Equipment industry 23.9%.


Return on Equity

High ROE: EUZ's Return on Equity (16.4%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Eckert & Ziegler Strahlen- und Medizintechnik's financial position?


Financial Position Analysis

Short Term Liabilities: EUZ's short term assets (€131.5M) exceeds its short term liabilities (€34.0M)

Long Term Liabilities: EUZ's short term assets (€131.5M) exceeds its long term liabilities (87.8M)


Debt to Equity History and Analysis

Debt Level: EUZ's debt to equity ratio (13.5%) is considered satisfactory.

Reducing Debt: EUZ's debt to equity ratio has reduced from 21.5% to 13.5% over the past 5 years.

Debt Coverage: EUZ's debt is well covered by operating cash flow (198.3%).

Interest Coverage: EUZ's interest payments on its debt are well covered by EBIT (36.2x coverage).


Balance Sheet

Inventory Level: EUZ has a high level of physical assets or inventory.

Debt Coverage by Assets: EUZ's debt is covered by short term assets (assets are 7.1x debt).


Next Steps

Dividend

What is Eckert & Ziegler Strahlen- und Medizintechnik's current dividend yield, its reliability and sustainability?

0.66%

Current Dividend Yield


Dividend Yield vs Market

company0.7%marketbottom25%1.3%markettop25%3.7%industryaverage1.4%forecastin3Years1.0%

Current dividend yield vs market & industry

Notable Dividend: EUZ's dividend (0.66%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.35%).

High Dividend: EUZ's dividend (0.66%) is low compared to the top 25% of dividend payers in the German market (3.72%).


Stability and Growth of Payments

Stable Dividend: EUZ is not paying a notable dividend for the German market, therefore no need to check if payments are stable.

Growing Dividend: EUZ is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: EUZ is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EUZ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Eckert & Ziegler Strahlen- und Medizintechnik's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Andreas Eckert (59yo)

0yrs

Tenure

€722,895

Compensation

Dr. Andreas Eckert, PhD, is the Founder and Managing Partner of ELSA Eckert Life Science Accelerator GmbH. Dr. Exkert is the Founder of Eckert & Ziegler Strahlen & Medizintechnik AG and serves as its Chief ...


CEO Compensation Analysis

Compensation vs Market: Andreas's total compensation ($USD801.52K) is below average for companies of similar size in the German market ($USD1.17M).

Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.3yrs

Average Tenure

55yo

Average Age

Experienced Management: EUZ's management team is considered experienced (4.3 years average tenure).


Board Age and Tenure

1.6yrs

Average Tenure

66yo

Average Age

Experienced Board: EUZ's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Andreas Eckert (59yo)

    Chairman of Executive Board & CEO

    • Tenure: 0yrs
    • Compensation: €722.90k
  • Harald Hasselmann (52yo)

    Head of Radiation Therapy Segment & Member of the Executive Board

    • Tenure: 2.8yrs
    • Compensation: €347.34k
  • Gunnar Mann (52yo)

    Head of Intragroup Services

    • Tenure: 7.8yrs
  • Joe Hathcock

    Vice President of Eckert & Ziegler Isotope Products Inc

    • Tenure: 0yrs
  • Frank Yeager

    Head of Isotope Products Segment

    • Tenure: 0yrs
  • Ivan Simmer

    Managing Director of Eckert & Ziegler Cesio s.r.o.

    • Tenure: 5.8yrs
  • Lutz Helmke (58yo)

    Member of Executive Board

    • Tenure: 1.2yrs
    • Compensation: €220.91k

Board Members

  • Frank Perschmann (66yo)

    Member of Supervisory Board

    • Tenure: 0.5yrs
    • Compensation: €4.95k
  • Wolfgang Maennig (59yo)

    Chairman of Supervisory Board

    • Tenure: 6.5yrs
    • Compensation: €35.00k
  • Edgar Löffler (66yo)

    Member of Supervisory Board

    • Tenure: 0.8yrs
    • Compensation: €291.00k
  • Helmut Grothe

    Deputy Chairman of the Supervisory Board

    • Tenure: 2.3yrs
    • Compensation: €26.00k
  • Albert Rupprecht

    Member of Supervisory Board

    • Tenure: 2.5yrs
    • Compensation: €17.00k
  • Jutta Ludwig

    Member of Supervisory Board

    • Tenure: 0.9yrs

Company Information

Eckert & Ziegler Strahlen- und Medizintechnik AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Ticker: EUZ
  • Exchange: XTRA
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €929.643m
  • Shares outstanding: 5.15m
  • Website: https://www.ezag.com

Number of Employees


Location

  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Robert-Rössle-Strasse 10
  • Berlin
  • 13125
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EUZDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 1999
EUZXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURMay 1999
0NZYLSE (London Stock Exchange)YesOrdinary SharesGBEURMay 1999
EUZdBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURMay 1999

Biography

Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/18 21:03
End of Day Share Price2019/11/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.